Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous peripheral blood CD34+ hematopoietic stem cells
- Development stage
- Unknown
- Lead developer
- Tokai University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional, Intramuscular, Intra-arterial
01
Overview
Autologous peripheral blood CD34+ hematopoietic stem cells are a cell therapy product that leverages the regenerative and angiogenic potential of CD34-positive progenitor cells. Collected from the patient's own blood after mobilization (typically with G-CSF), these cells are enriched for the CD34 surface marker and delivered to sites of tissue damage, such as non-union fractures or ischemic limbs. The therapeutic effect is primarily mediated by the secretion of pro-angiogenic growth factors and the potential for these cells to differentiate into endothelial cells, thereby promoting the formation of new microvasculature and facilitating tissue repair and bone healing. This specific therapeutic approach has been extensively developed in Japan with support from the Japan Agency for Medical Research and Development (AMED) for regenerative medicine applications.
- Other names
- autologous CD34+ cellsperipheral blood CD34+ cellsautologous CD34-positive cellsautologous peripheral blood CD34+ cells
Beyond the preview
Go deeper on autologous peripheral blood CD34+ hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous peripheral blood CD34+ hematopoietic stem cells.